29 March 2020: Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has obtained first marketing approval in Japan for an in vitro diagnostic medical device, β€œ2019-nCoV Fluorescence Detection Real-Time RT-PCR Kit”. Delivery of this product to medical institutions is scheduled for March 2020.

06 March 2020: Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) provides notice that Dr. Yu Sunakawa, Associate Professor in the Department of Clinical Oncology at the St. Marianna University School of Medicine, presented his research findings at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020), held in San Francisco, California, the United States, from January 23 to 25, 2020.

06 March 2020: Sysmex and the Kobe City Eye Hospital Sign a Comprehensive Collaboration Agreement

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and the Kobe City Eye Hospital (Location: Kobe, Japan; Director: Yasuo Kurimoto) announce that they have entered into a comprehensive collaboration agreement related to the clinical implementation of genomic medicine for hereditary retinal degenerative diseases. The agreement was signed in February 2020.